Trials / Unknown
UnknownNCT04497402
Sex-Informed Data in the COVID-19 Pandemic.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 88 (estimated)
- Sponsor
- University of Roma La Sapienza · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Accepted
Summary
Sex and gender matter to health equity, especially in a pandemic. Sex (a biological attribute) and gender (a social construct) may influence an individual's susceptibility, vulnerability and exposure to infectious disease. In previous coronavirus epidemics (SARS and MERS), male sex was associated with worse outcomes. Both immune and the hemostatic response display ample sexual dimorphism. The primary aim of the study is to determine whether sex differences in biomarkers of platelet and immune function, gut microbiome, clinical characteristics, therapy, clinical cost sensitive outcomes (i.e. in-hospital transition of care, case severity, and mortality due to COVID-19) exist in patients affected by COVID-19.
Conditions
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2022-06-01
- Completion
- 2022-12-01
- First posted
- 2020-08-04
- Last updated
- 2022-01-13
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04497402. Inclusion in this directory is not an endorsement.